View ValuationCynata Therapeutics 将来の成長Future 基準チェック /16Cynata Therapeuticsの収益は年間50.4%で減少すると予測されていますが、年間収益は年間13.8%で増加すると予想されています。EPS は年間47.5%で減少すると予想されています。主要情報-50.4%収益成長率-47.55%EPS成長率Biotechs 収益成長25.2%収益成長率13.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日02 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 08Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listingお知らせ • May 04Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Transaction Features: Subsequent Direct Listingお知らせ • Dec 15Cynata Therapeutics Limited Completes Patient Enrolment in Phase 2 aGvHD Clinical TrialCynata Therapeutics Limited announced that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD). A total of 65 participants have been enrolled in the trial across numerous clinical centres in the US, Europe and Australia. Each participant was randomised to receive either steroids plus CYP-001, or steroids plus placebo. The trial involves a 100-day primary evaluation period, which is expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint is Overall Response Rate at Day 28. In a successful Phase 1 trial in patients with SR-aGvHD, 87% of patients showed an Overall Response, 53% showed a Complete Response, and 60% survival for at least two years. Importantly, there were no serious adverse events or safety concerns related to CYP-001 treatment. This ground-breaking trial led to two publications in the prestigious journal Nature Medicine. CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of aGvHD.お知らせ • Sep 18Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025.お知らせ • Apr 07Cynata Therapeutics Limited Announces Positive Efficacy Data Observed in Preclinical Studies Conducted with Cymerus Ipsc1-Derived Mscs in Models of Ischaemic Heart DiseaseCynata Therapeutics Limited announced positive efficacy data observed in preclinical studies conducted with Cynata's Cymerus™? iPSC-derived MSCs in models of ischaemic heart disease. MSCs have the potential to treat ischaemic heart disease, the leading cause of death worldwide, by releasing proteins and other bioactive molecules. This project evaluated a new, minimally invasive method to deliver beneficial molecules from MSCs over an extended period, using a retrievable encapsulation device. The device, which can be implanted under the skin, protects the cells while still permitting the release of molecules into the circulation. Key Highlights. In a rat model of heart attack (known as an ischaemia-reperfusion model), treatment with encapsulated Cymerus™? MSCs resulted in the following: Significantly improved heart function and a reduction in harmful structural changes in the heart, compared to controls treated with encapsulated placebo. Less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups. Encapsulated Cymerus MSCs were still alive and functional twelve weeks after implantation. Cymerus™? M SCs produce proteins that support tissue health, aid in healing, help to protect cells from damage, play a role in regulating the immune system and reduce inflammation. In an in vitro model of human heart tissues created and grown in a laboratory (known as "cardiac spheroids"), tissues treated with proteins from Cymerus™? Mscs showed improved survival and function compared to controls treated with placebo. Chief Investigator of the study, Associate Professor Shiang (Max) Lim (Head, Cardiac Regeneration Laboratory, St Vincent's Institute of Medical Research, Melbourne) said: This study demonstrates the utility of a clinically viable, minimally invasive method for sustained delivery of active molecules released by Cymerus™? MScs, which has the potential to address a major gap in the treatment of ischaemic heart disease".お知らせ • Jan 23Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listingお知らせ • Dec 06Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listingお知らせ • Sep 24Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024.お知らせ • Apr 09Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical TrialCynata Therapeutics Limited announced the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). CYP-006TK is Cynata's Cymerus iPSC-derived MSC topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing. Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if therapy is unsuccessful, amputation may be necessary. In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU. The pre-specified sample size has now been reached, with a total of 30 patients with DFU randomised on a 1:1 basis to receive either: (i) CYP-006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or (ii) standard of care treatment throughout the study. In accordance with the study protocol, patients will be followed for 24 weeks following treatment initiation, which means that the last patient visit in this trial is expected to occur around September 2024.お知らせ • Mar 06Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001Cynata Therapeutics Limited confirmed that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a Phase 1 clinical trial in steroid-resistant aGvHD. The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation[4] for the treatment of aGvHD. aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. It arises when immune cells in the transplant (the graft) attack the recipient's tissues (the host) as "foreign". In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD. This global Phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. Additional details on the trial may be found at clinicaltrials.gov using identifier NCT05643638. The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. The first patient was enrolled in the USA.お知らせ • Oct 11Cynata Therapeutics Limited Announces Resignation of David Atkins as DirectorCynata Therapeutics Limited that Dr. David Atkins has informed the Board that he will not be standing for re-election as a Director at the Company's Annual General Meeting (AGM) to be held on 13 November 2023 and accordinglywill cease to be a Director from the conclusion of the AGM.お知らせ • Jun 30+ 1 more updateCynata Therapeutics Limited Announces Management AppointmentsCynata Therapeutics Limited announced the appointment of Dr. Kilian Kelly to the position of Managing Director, effective 1 July 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014. The company is also pleased to welcome Dr. David Atkins to the Board of Directors. Dr. Atkins is the Managing Partner of BioScience Managers, an international healthcare investment firm and a major Cynata shareholder. Dr. Stewart Washer will step down from his position as a non-executive director. Dr. Atkins has over 25 years' experience as a global leader in a broad range of life science and healthcare businesses including Johnson & Johnson and Danaher. He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Furthermore, David has founded or assumed leadership roles in 3 start-up businesses in gene therapy, molecular and cellular cancer diagnostics and clinical genomics. Given Dr. Atkins' executive role with Bioscience Managers (a substantial holder of Cynata), the Board considers that Dr. Atkins is not an independent director.お知らせ • Jan 30Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical TrialCynata Therapeutics Limited has announced that it has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease (aGvHD) from Advarra Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is an essential step in the process of opening clinical study sites and to commencing a clinical trial in humans in the United States. Cynata is now finalising contractual and logistic arrangements with individual sites (hospitals) to prepare for patient recruitment. This follows the landmark clearance of Cynata's Investigational New Drug (IND) application in 2022 and grant of Orphan Drug Status for CYP-001. The proposed clinical trial is titled "A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vsCorticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease" and is expected to be conducted in around 60 patients at sites in the United States, Europe and Australia.お知らせ • Jan 09Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCsCynata Therapeutics Limited has announced that a Notice of Acceptance has been received from IP Australia, the intellectual property office of the Australian Government, for a patent application covering its proprietary CymerusTM mesenchymal stem cell (MSC) platform technology. The patent application entitled "Method for Treating Allergic Airways Disease (AAD)/Asthma" is wholly owned by Cynata and describes a novel method of use of Cynata's proprietary Cymerus MSC products in treating diseases of the lungs and airways. The Notice of Acceptance is sent to the applicant when IP Australia intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products. Cynata anticipates that the patent will be granted around mid-March 2023, with an expiration date of 31 August 2038.業績と収益の成長予測OTCPK:CYYN.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20283-26-27-2716/30/20272-15-15-1516/30/20262-8-8-8112/31/20252-8-8-8N/A9/30/20252-9-8-8N/A6/30/20252-9-9-9N/A3/31/20252-9-8-8N/A12/31/20242-9-8-8N/A9/30/20242-9-9-9N/A6/30/20242-10-10-10N/A3/31/20242-12-11-11N/A12/31/20232-14-12-12N/A9/30/20232-14-13-13N/A6/30/20232-14-14-14N/A3/31/20232-12-12-12N/A12/31/20223-9-10-10N/A9/30/20225-7-7-7N/A6/30/20228-5-3-3N/A3/31/20228-5-2-2N/A12/31/20218-4-1-1N/A9/30/20215-6-3-3N/A6/30/20212-8-5-5N/A3/31/20212-7-5-5N/A12/31/20203-6-5-5N/A9/30/20205-5-4-4N/A6/30/20207-4-3-3N/A3/31/20206-6-5-5N/A12/31/20194-8-7-7N/A9/30/20193-8N/A-7N/A6/30/20191-8N/A-7N/A3/31/20191-7N/A-6N/A12/31/20181-6N/A-5N/A9/30/20181-5N/A-4N/A6/30/20181-5N/A-4N/A3/31/20181-5N/A-4N/A12/31/20171-5N/A-5N/A9/30/20172-5N/A-4N/A6/30/20172-5N/A-4N/A3/31/20172-4N/A-3N/A12/31/20162-3N/A-2N/A9/30/20161-4N/A-3N/A6/30/20161-5N/A-4N/A3/31/20161-5N/A-4N/A12/31/20151-5N/A-4N/A9/30/20151-4N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CYYN.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CYYN.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: CYYN.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CYYN.Fの収益 ( 13.8% ) US市場 ( 12.8% ) よりも速いペースで成長すると予測されています。高い収益成長: CYYN.Fの収益 ( 13.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CYYN.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 01:41終値2026/06/30 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cynata Therapeutics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Darren VincentShaw and Partners LimitedNicholas LauTaylor Collison Limited
お知らせ • May 08Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
お知らせ • May 04Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 15Cynata Therapeutics Limited Completes Patient Enrolment in Phase 2 aGvHD Clinical TrialCynata Therapeutics Limited announced that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD). A total of 65 participants have been enrolled in the trial across numerous clinical centres in the US, Europe and Australia. Each participant was randomised to receive either steroids plus CYP-001, or steroids plus placebo. The trial involves a 100-day primary evaluation period, which is expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint is Overall Response Rate at Day 28. In a successful Phase 1 trial in patients with SR-aGvHD, 87% of patients showed an Overall Response, 53% showed a Complete Response, and 60% survival for at least two years. Importantly, there were no serious adverse events or safety concerns related to CYP-001 treatment. This ground-breaking trial led to two publications in the prestigious journal Nature Medicine. CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of aGvHD.
お知らせ • Sep 18Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025.
お知らせ • Apr 07Cynata Therapeutics Limited Announces Positive Efficacy Data Observed in Preclinical Studies Conducted with Cymerus Ipsc1-Derived Mscs in Models of Ischaemic Heart DiseaseCynata Therapeutics Limited announced positive efficacy data observed in preclinical studies conducted with Cynata's Cymerus™? iPSC-derived MSCs in models of ischaemic heart disease. MSCs have the potential to treat ischaemic heart disease, the leading cause of death worldwide, by releasing proteins and other bioactive molecules. This project evaluated a new, minimally invasive method to deliver beneficial molecules from MSCs over an extended period, using a retrievable encapsulation device. The device, which can be implanted under the skin, protects the cells while still permitting the release of molecules into the circulation. Key Highlights. In a rat model of heart attack (known as an ischaemia-reperfusion model), treatment with encapsulated Cymerus™? MSCs resulted in the following: Significantly improved heart function and a reduction in harmful structural changes in the heart, compared to controls treated with encapsulated placebo. Less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups. Encapsulated Cymerus MSCs were still alive and functional twelve weeks after implantation. Cymerus™? M SCs produce proteins that support tissue health, aid in healing, help to protect cells from damage, play a role in regulating the immune system and reduce inflammation. In an in vitro model of human heart tissues created and grown in a laboratory (known as "cardiac spheroids"), tissues treated with proteins from Cymerus™? Mscs showed improved survival and function compared to controls treated with placebo. Chief Investigator of the study, Associate Professor Shiang (Max) Lim (Head, Cardiac Regeneration Laboratory, St Vincent's Institute of Medical Research, Melbourne) said: This study demonstrates the utility of a clinically viable, minimally invasive method for sustained delivery of active molecules released by Cymerus™? MScs, which has the potential to address a major gap in the treatment of ischaemic heart disease".
お知らせ • Jan 23Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 06Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 24Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024.
お知らせ • Apr 09Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical TrialCynata Therapeutics Limited announced the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). CYP-006TK is Cynata's Cymerus iPSC-derived MSC topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing. Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if therapy is unsuccessful, amputation may be necessary. In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU. The pre-specified sample size has now been reached, with a total of 30 patients with DFU randomised on a 1:1 basis to receive either: (i) CYP-006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or (ii) standard of care treatment throughout the study. In accordance with the study protocol, patients will be followed for 24 weeks following treatment initiation, which means that the last patient visit in this trial is expected to occur around September 2024.
お知らせ • Mar 06Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001Cynata Therapeutics Limited confirmed that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a Phase 1 clinical trial in steroid-resistant aGvHD. The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation[4] for the treatment of aGvHD. aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. It arises when immune cells in the transplant (the graft) attack the recipient's tissues (the host) as "foreign". In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD. This global Phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. Additional details on the trial may be found at clinicaltrials.gov using identifier NCT05643638. The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. The first patient was enrolled in the USA.
お知らせ • Oct 11Cynata Therapeutics Limited Announces Resignation of David Atkins as DirectorCynata Therapeutics Limited that Dr. David Atkins has informed the Board that he will not be standing for re-election as a Director at the Company's Annual General Meeting (AGM) to be held on 13 November 2023 and accordinglywill cease to be a Director from the conclusion of the AGM.
お知らせ • Jun 30+ 1 more updateCynata Therapeutics Limited Announces Management AppointmentsCynata Therapeutics Limited announced the appointment of Dr. Kilian Kelly to the position of Managing Director, effective 1 July 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014. The company is also pleased to welcome Dr. David Atkins to the Board of Directors. Dr. Atkins is the Managing Partner of BioScience Managers, an international healthcare investment firm and a major Cynata shareholder. Dr. Stewart Washer will step down from his position as a non-executive director. Dr. Atkins has over 25 years' experience as a global leader in a broad range of life science and healthcare businesses including Johnson & Johnson and Danaher. He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Furthermore, David has founded or assumed leadership roles in 3 start-up businesses in gene therapy, molecular and cellular cancer diagnostics and clinical genomics. Given Dr. Atkins' executive role with Bioscience Managers (a substantial holder of Cynata), the Board considers that Dr. Atkins is not an independent director.
お知らせ • Jan 30Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical TrialCynata Therapeutics Limited has announced that it has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease (aGvHD) from Advarra Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is an essential step in the process of opening clinical study sites and to commencing a clinical trial in humans in the United States. Cynata is now finalising contractual and logistic arrangements with individual sites (hospitals) to prepare for patient recruitment. This follows the landmark clearance of Cynata's Investigational New Drug (IND) application in 2022 and grant of Orphan Drug Status for CYP-001. The proposed clinical trial is titled "A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vsCorticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease" and is expected to be conducted in around 60 patients at sites in the United States, Europe and Australia.
お知らせ • Jan 09Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCsCynata Therapeutics Limited has announced that a Notice of Acceptance has been received from IP Australia, the intellectual property office of the Australian Government, for a patent application covering its proprietary CymerusTM mesenchymal stem cell (MSC) platform technology. The patent application entitled "Method for Treating Allergic Airways Disease (AAD)/Asthma" is wholly owned by Cynata and describes a novel method of use of Cynata's proprietary Cymerus MSC products in treating diseases of the lungs and airways. The Notice of Acceptance is sent to the applicant when IP Australia intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products. Cynata anticipates that the patent will be granted around mid-March 2023, with an expiration date of 31 August 2038.